KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBITDA (2016 - 2025)

Rigel Pharmaceuticals has reported EBITDA over the past 16 years, most recently at $23.2 million for Q4 2025.

  • For Q4 2025, EBITDA rose 39.12% year-over-year to $23.2 million; the TTM value through Dec 2025 reached $125.5 million, up 418.63%, while the annual FY2025 figure was $125.5 million, 418.63% up from the prior year.
  • EBITDA for Q4 2025 was $23.2 million at Rigel Pharmaceuticals, down from $28.4 million in the prior quarter.
  • Over five years, EBITDA peaked at $61.1 million in Q2 2025 and troughed at -$26.3 million in Q1 2022.
  • A 5-year average of $3.1 million and a median of -$2.0 million in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: tumbled 162.89% in 2022 and later skyrocketed 13569.57% in 2025.
  • Year by year, EBITDA stood at -$21.4 million in 2021, then skyrocketed by 109.71% to $2.1 million in 2022, then decreased by 5.44% to $2.0 million in 2023, then skyrocketed by 747.15% to $16.7 million in 2024, then skyrocketed by 39.12% to $23.2 million in 2025.
  • Business Quant data shows EBITDA for RIGL at $23.2 million in Q4 2025, $28.4 million in Q3 2025, and $61.1 million in Q2 2025.